Clinical Trials on Alpha 1-Antitrypsin Deficiency in New Zealand
Total 77 results
-
Arrowhead PharmaceuticalsCompleted
-
Dicerna Pharmaceuticals, Inc.WithdrawnAlpha 1-Antitrypsin DeficiencyNew Zealand
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyCompleted
-
TakedaEnrolling by invitationAlpha1-Antitrypsin DeficiencyUnited Kingdom, Germany, United States, Austria, Portugal
-
Baxalta now part of ShireCompletedAlpha 1-Antitrypsin DeficiencyNew Zealand, Australia
-
Baxalta now part of ShireBaxter Healthcare, Ltd. (New Zealand), Baxter Healthcare Pty. Ltd. (Australia)CompletedAlpha 1-Antitrypsin DeficiencyAustralia, New Zealand
-
TakedaTakeda Development Center Americas, Inc.RecruitingAlpha1-Antitrypsin DeficiencyUnited States, Belgium, Switzerland, Canada, Australia, Germany, United Kingdom, Austria, France, Spain, Portugal, Italy, Poland
-
Grifols Therapeutics LLCEnrolling by invitationPulmonary Emphysema in Alpha-1 Antitrypsin DeficiencyUnited States, New Zealand, Denmark, Australia, Finland, Estonia, Canada, Poland, Russian Federation, Sweden, France
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)CompletedAlpha 1 Antitrypsin Deficiency | AATDUnited States
-
Inhibrx, Inc.CompletedAlpha-1 Antitrypsin Deficiency | AATDUnited States, New Zealand, United Kingdom
-
Baxalta now part of ShireBaxalta Innovations GmbH, now part of ShireTerminatedChronic Obstructive Pulmonary Disease | Alpha1-antitrypsin DeficiencyUnited States, Canada, Australia
-
Dicerna Pharmaceuticals, Inc., a Novo Nordisk companyActive, not recruitingAlpha 1-Antitrypsin DeficiencyUnited Kingdom, United States, Ireland, Belgium, New Zealand, Spain, Netherlands, Portugal, Canada, Australia, France, Austria, Germany, Sweden
-
Grifols Therapeutics LLCActive, not recruitingPulmonary Emphysema in Alpha-1 PI DeficiencyUnited States, Australia, Denmark, New Zealand, Estonia, Poland, Russian Federation, Sweden, Brazil, Canada, France, Finland
-
Grifols Therapeutics LLCCompletedAlpha 1-Antitrypsin DeficiencyUnited States
-
Grifols Therapeutics LLCCompletedAlpha 1-Antitrypsin DeficiencyUnited States, United Kingdom
-
Vertex Pharmaceuticals IncorporatedActive, not recruitingAlpha-1 Antitrypsin DeficiencyUnited States, United Kingdom, Germany, Ireland
-
Arrowhead PharmaceuticalsCompletedAlpha 1-Antitrypsin DeficiencyUnited States, Spain, Netherlands, Germany, Italy, Portugal
-
Vertex Pharmaceuticals IncorporatedTerminatedAlpha 1-Antitrypsin DeficiencyUnited States, Germany, Canada, Ireland
-
University of Alabama at BirminghamNational Institutes of Health (NIH); Mereo BioPharmaCompletedEmphysema or COPD | Alpha-1 Antitrypsin Deficiency (AATD) | Pi*ZZ, Pi*SZ, Pi*Null, Another Rare Phenotype/Genotype Known to be Associated With Either Low or Functionally Impaired AAT Including F or I MutationsUnited States
-
CSL BehringCompletedEmphysema | Alpha 1-proteinase Inhibitor DeficiencyAustralia, Canada, Czech Republic, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden
-
Inhibrx, Inc.RecruitingEmphysema | Alpha 1-Antitrypsin DeficiencyUnited States, Australia, United Kingdom, New Zealand
-
Gerard TurinoCompletedEmphysema | Alpha 1-Antitrypsin DeficiencyUnited States, Canada
-
Columbia UniversityAlpha-1 Foundation; Stony Wold-Herbert Fund, Inc.CompletedChronic Obstructive Pulmonary Disease | Emphysema | Alpha-1 Antitrypsin DeficiencyUnited States
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI); Alpha-1 FoundationActive, not recruitingAlpha 1-Antitrypsin Deficiency | Genetic DiseaseUnited States
-
Alpha-1 FoundationCompletedChronic Obstructive Pulmonary Disease | Alpha-1 Antitrypsin DeficiencyUnited States, Puerto Rico
-
John LevineNational Cancer Institute (NCI)CompletedGVHD | Graft-versus-host-diseaseUnited States
-
Columbia UniversityAlpha-1 FoundationRecruitingChronic Obstructive Pulmonary Disease | Acute Exacerbation Copd | Alpha-1 Anti-trypsin DeficiencyUnited States
-
CSL BehringCompletedEmphysema | Alpha1-proteinase Inhibitor DeficiencyAustralia, Russian Federation, United States, Denmark, Estonia, Finland, Germany, Ireland, Poland, Romania, Sweden, Canada, Czech Republic
-
Arbor Research Collaborative for HealthNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingLiver Diseases | Alpha 1-Antitrypsin Deficiency | Alagille SyndromeUnited States, Canada
-
Grifols Therapeutics LLCTerminatedType 1 Diabetes MellitusUnited States
-
Grifols Therapeutics LLCTerminatedCOVID-19United States, Brazil, Chile, Colombia, Mexico
-
Murdoch Childrens Research InstituteRoyal Children's HospitalCompletedPrimary Immunodeficiency | Invasive Pneumococcal Disease, Protection Against | Invasive Pneumococcal Disease, Recurrent Isolated, 1 | Invasive Pneumococcal Disease, Recurrent Isolated, 2Australia, New Zealand
-
Nina BhardwajNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsCompletedHIV-1 Infected Adults With Chronic HIV-1 InfectionUnited States
-
IpsenTerminatedPrimary Insulin-like Growth Factor-1 DeficiencyUnited States
-
Ultragenyx Pharmaceutical IncCompletedGlucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)United States, Spain, Australia, France, Israel, Italy, United Kingdom
-
Janssen Sciences Ireland UCCompletedImmunodeficiency Virus Type 1, HumanUnited States, France, Poland, United Kingdom, Belgium, Germany, Spain, Canada, Russian Federation, Puerto Rico
-
Ultragenyx Pharmaceutical IncTerminatedGlucose Transporter Type 1 Deficiency Syndrome (Glut1 DS)United States, Spain, France, Germany, Italy, United Kingdom
-
Kirby InstituteGilead Sciences; Melanoma Institute Australia; St Vincent's Hospital, Sydney; Royal... and other collaboratorsActive, not recruitingCOVID-19 | Cancer | Primary Immune Deficiency Disorder | HIV-1-infection | Immunosuppression DisordersAustralia
-
ST Pharm Co., Ltd.RecruitingHIV-1-infectionUnited States
-
Gilead SciencesActive, not recruitingHIV-1-infectionUnited States, Spain, France, Taiwan, Japan, Thailand, Dominican Republic, Germany, Canada, Italy, South Africa
-
Genzyme, a Sanofi CompanyCompletedGaucher Disease, Type 1 | Cerebroside Lipidosis Syndrome | Glucocerebrosidase Deficiency Disease | Glucosylceramide Beta-Glucosidase Deficiency Disease | Gaucher Disease, Non-Neuronopathic FormUnited States, United Kingdom, Spain, Italy, Brazil, Canada, Poland
-
Genzyme, a Sanofi CompanyCompletedGaucher Disease, Type 1 | Cerebroside Lipidosis Syndrome | Glucocerebrosidase Deficiency Disease | Glucosylceramide Beta-Glucosidase Deficiency Disease | Gaucher Disease, Non-Neuronopathic FormUnited States, Israel, Mexico, Russian Federation, Argentina, Italy
-
Icahn School of Medicine at Mount SinaiNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Gilead SciencesTerminatedHuman Immunodeficiency Virus Type 1 (HIV-1) InfectionUnited States
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID); National Institutes... and other collaboratorsActive, not recruitingHuman Immunodeficiency Virus I Infection | Immunodeficiency Virus Type 1, Human | Human Immunodeficiency Virus Type 1United States
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute of Mental Health...CompletedHIV Infections | HIV-1United States, Puerto Rico
-
Gilead SciencesActive, not recruitingPre-Exposure Prophylaxis of HIV-1 InfectionUnited States, Austria, Denmark, United Kingdom, Netherlands, Italy, Germany, Canada, Ireland, France, Spain
-
Ultragenyx Pharmaceutical IncTerminatedGlucose Transporter Type 1 Deficiency SyndromeUnited States, Spain, Denmark, United Kingdom, Australia
-
Gilead SciencesCompletedHIV Infections | Acquired Immunodeficiency Syndrome | HIV-1United States, Canada
-
Aeglea BiotherapeuticsCompletedArginase I Deficiency | HyperargininemiaUnited States, Italy, Canada, France, United Kingdom, Austria, Germany